Efficacy and safety of CKD-495 in acute and chronic gastritis: A Phase III superiority clinical trial.
Seung Young SeoSoo Teik LeeSung Kook KimHoon Jai ChunGeun Am SongDong Ho LeeJae Jun KimJin Il KimYoung Chan LeeTae Nyeun KimSam Ryong JeeSeon-Young ParkJae Gyu KimJong-Jae ParkSang Gyun KimJae Myung ParkJung Ho ParkShin Jung ParkOh Young LeePublished in: Medicine (2023)
These results demonstrate that CKD-495 75 mg is superior to AAF 60 mg in terms of the endoscopic improvement rate of erosions in patients with acute or chronic gastritis. This new mucoprotective agent, CKD-495, can be considered the therapy of choice for symptomatic relief and healing of gastritis.
Keyphrases
- phase iii
- helicobacter pylori
- clinical trial
- helicobacter pylori infection
- chronic kidney disease
- open label
- phase ii
- double blind
- drug induced
- liver failure
- placebo controlled
- ultrasound guided
- respiratory failure
- randomized controlled trial
- acute respiratory distress syndrome
- bone marrow
- aortic dissection
- smoking cessation